Key takeaways
- 3/3 SMA modalities (Zolgensma, nusinersen, risdiplam) fully covered under NPHC and MOH UAE
- $1.5-1.8M Negotiated GCC Zolgensma WAC vs $2.125M US list price, with an outcomes-based milestone rebate
- SAR 20-25M Estimated lifetime risdiplam cost per Type 2/3 patient (age 2 to 30) — the NPHC budget exposure driving outcomes contracting
NPHC's SMA programme, the most structured rare-disease coverage model in the GCC, pairs comprehensive 3-modality access with a GCC-first outcomes-based rebate on Zolgensma.
NPHC's SMA coverage programme is, alongside PNH, the most structured rare-disease programme in Saudi Arabia. Coverage criteria are explicit: SMA Type 1 patients with zero SMN1 copies receive Zolgensma if aged ≤2 years and weighing ≤13.5 kg, or nusinersen/risdiplam otherwise; Type 2/3 patients receive nusinersen or risdiplam; and newborn-screening-identified pre-symptomatic infants (any SMN2 copy count) receive Zolgensma first-line if ≤2 years old. Continuation criteria for chronic therapies require a motor-function assessment every 12 months, with discontinuation triggered by no improvement or a ≥20% decline. Novartis negotiated a GCC Zolgensma price of approximately $1.5-1.8 million one-time, against a US list price of $2.125 million, with a milestone-based rebate if the patient does not achieve independent sitting by 24 months (Type 1/NBS cohort). Gene therapy administration runs through four designated GCC centres: KAMC and KFSH&RC in Riyadh, Sidra Medicine in Doha, and SKMC in Abu Dhabi, covering an estimated 60-80 annual GCC cases.
Risdiplam (Evrysdi), SFDA- and UAE MOH-registered since 2022, is NPHC-listed for Types 1-3 at an annual GCC WAC of SAR 700,000-800,000, roughly 60-70% of US WAC after tender negotiation, with Roche's GCC rare-disease programme covering home delivery for the oral formulation. Nusinersen costs SAR 350,000-400,000 per injection on a quarterly maintenance schedule, with first-year loading dosing reaching SAR 1.4-1.6 million. Over a Type 2/3 patient's lifetime (diagnosis at age 2 through age 30), cumulative risdiplam therapy cost reaches an estimated SAR 20-25 million, a significant NPHC budget exposure that makes the SMA programme's outcomes-based and continuation-monitoring architecture the reference model other GCC rare-disease programmes are now built to follow.
GCC SMA agent access status — 2026
| Drug (Brand / INN) | SFDA / GCC Registration Status | NPHC / MOH Coverage Pathway | GCC Pricing | Key Access Barrier |
|---|---|---|---|---|
| Zolgensma (onasemnogene abeparvovec) | SFDA 2021; NPHC listed | NPHC covers Type 1 + NBS pre-symptomatic (≤2y, ≤13.5kg) | ~$1.5-1.8M one-time (vs $2.125M US) | Outcomes-based milestone rebate at 24-month motor assessment |
| Evrysdi (risdiplam) | SFDA 2022; MOH UAE 2022 | NPHC listed Types 1-3; 12-month continuation review | ~SAR 700,000-800,000/year (~60-70% of US WAC) | Growing oral-route preference vs nusinersen in Type 2/3 |
Sources: NPHC SMA programme guidelines 2023; Novartis GCC access documentation; NPHC Zolgensma programme documentation 2022; Novartis GCC PSP data; Saudi MOH SMA drug procurement data 2023; NPHC SMA programme budget review.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- What are NPHC's exact SMA coverage and continuation criteria across all three treatment modalities, and how does newborn screening integrate? • Full NPHC SMA coverage-criteria matrix by type and modality • continuation/discontinuation motor-function assessment protocol • NBS-triggered Zolgensma first-line pathway
- How does Zolgensma's GCC outcomes-based milestone rebate work, and what does it imply for other gene-therapy market access negotiations? • Zolgensma GCC pricing and milestone-rebate structure • precedent analysis for outcomes-based contracting applicability to other high-cost gene therapies (e.g., SCD gene therapy)
- How do risdiplam and nusinersen chronic-therapy costs compare over a patient's lifetime, and what does this mean for NPHC budget planning? • Risdiplam vs nusinersen annual and lifetime cost comparison • NPHC SMA budget exposure modelling and oral-route preference trend among Type 2/3 families
What's inside
-
1 · NPHC SMA Programme — the Most Mature GCC Rare-Disease Model 5 pp
- Why NPHC's SMA programme ranks alongside PNH as the most structured rare-disease coverage model in Saudi Arabia
- How the outcomes-based and continuation-monitoring architecture built for SMA is becoming the reference other GCC rare-disease programmes follow
-
2 · Coverage Criteria by Modality and SMA Type 5 pp
- Exact NPHC criteria: Zolgensma for Type 1 patients aged 2 or under and weighing 13.5kg or less with zero SMN1 copies, nusinersen or risdiplam otherwise
- The newborn-screening pathway giving pre-symptomatic infants, any SMN2 copy count, first-line Zolgensma access if aged 2 or under
-
3 · Zolgensma GCC Pricing and Outcomes-Based Milestone Rebate 5 pp
- Novartis's negotiated GCC price of $1.5-1.8 million versus the $2.125 million US list price
- How the milestone rebate triggers if a patient does not achieve independent sitting by 24 months
-
4 · Risdiplam and Nusinersen — Chronic Therapy Cost Comparison 5 pp
- Annual cost comparison: risdiplam at SAR 700,000-800,000 versus nusinersen's SAR 350,000-400,000 per injection with SAR 1.4-1.6 million first-year loading
- Why cumulative risdiplam cost reaches an estimated SAR 20-25 million over a Type 2/3 patient's lifetime from age 2 through age 30
-
5 · Newborn Screening and Pre-Symptomatic Access Pathway 3 pp
- How NBS-identified pre-symptomatic infants receive first-line Zolgensma access regardless of SMN2 copy count
- The four designated GCC gene-therapy administration centres: KAMC and KFSH&RC in Riyadh, Sidra Medicine in Doha, and SKMC in Abu Dhabi
-
6 · NPHC Budget Exposure and Continuation-Monitoring Framework 3 pp
- Modelling NPHC's budget exposure across an estimated 60-80 annual GCC Zolgensma cases plus ongoing risdiplam and nusinersen spend
- The 12-month motor-function assessment protocol that triggers discontinuation on no improvement or a 20% or greater decline
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx Spinal Muscular Atrophy Payer & HTA (GCC) is built for market access, HEOR, and pricing teams navigating NPHC's comprehensive coverage criteria, Zolgensma's outcomes-based milestone rebate, and chronic-therapy cost modelling across Saudi Arabia, UAE, and Qatar. Custom assessment in 72 hours.
- 1. Submit your requestSpecify indication, GCC payer focus (NPHC coverage criteria, outcomes-based contracting), and commercial question.
- 2. Scoping callAXLRx analyst confirms GCC market scope (KSA-first or pan-GCC), NPHC coverage analysis, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
This assessment is built from NPHC SMA programme guidelines, Novartis and Roche GCC access documentation, and Saudi MOH drug procurement data.
Key sources: NPHC SMA programme guidelines (2023); Novartis GCC access and Patient Support Programme documentation (2022-2023); Saudi MOH SMA drug procurement data (2023); NPHC SMA programme budget review.
- NPHC coverage and continuation criteria verified against NPHC SMA programme guidelines (2023)
- Zolgensma GCC pricing and milestone-rebate structure verified against Novartis GCC access documentation and NPHC Zolgensma programme documentation (2022)
- Risdiplam and nusinersen cost data verified against Saudi MOH SMA drug procurement data (2023)
- Lifetime cost modelling verified against NPHC SMA programme budget review
Frequently asked questions
Deliverables What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model (NPHC/MOH coverage grid or drug comparison data, depending on deliverable type), and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.
Sources What sources does AXLRx use, and how are findings verified?
AXLRx builds from primary sources only: NPHC SMA programme guidelines and budget review, Saudi MOH procurement records, and manufacturer access and patient-support programme documentation. No secondary summaries or market research reports. Every factual claim is independently verified before inclusion. Source citations are provided for all key data points in the delivered assessment.
Customisation Can I tailor the assessment to my specific question, geography, or comparator set?
Yes. The intake form captures your indication, target GCC market (KSA, UAE, Qatar, Kuwait, Oman, Bahrain), key comparator drugs, and the specific commercial question you need answered. A scoping call confirms scope before research starts. Custom extensions, such as additional GCC state deep-dives, pipeline agent profiles, or private-insurer coverage analysis, can be added to any standard assessment. Commission via the intake form to start.